Vivo Capital, OrbiMed Advisors and Enavate Sciences Invest In Compass Therapeutics

Vivo Capital is a healthcare investment firm focused on opportunities throughout the US and China. Specific areas of interest include biopharmaceuticals, specialty pharmaceuticals, and medical devices. The Firm looks to identify and work with companies at the development and commercial stage products in the US and at the revenue stage in China. Vivo Capital was established in 1996 and is headquartered in Palo Alto, California.

OrbiMed Advisors is a global healthcare centric investment firm that invests in medical device, life science, healthcare service, and medical diagnostic companies. OrbiMed maintains three investment disciplines including Public Equity, Private Equity, and Royalty Opportunities. OrbiMed's Public Equity group manages a series of public equity funds, including long/short event-driven funds and closed-end investment trusts that invests across all types of publicly-traded companies, from biopharmaceuticals to medical devices and healthcare services worldwide. OrbiMed's Private Equity group invests in start-ups through growth equity financings. OrbiMed prefers to be the lead investor and will consider opportunities across North America, Asia, Europe and Israel. OrbiMed's Royalty practice provides commercial-stage healthcare companies with non-dilutive structured debt capital. OrbiMed was formed in 1989 and is based in New York City.

Enavate Sciences is a platform dedicated to supporting therapeutic companies advancing medicines and enabling technologies with transformative potential to address patient need. Through the application of capital support and operational experience, Enavate strives to enable and empower a diverse portfolio of therapeutics companies to accelerate innovation. Enavate Sciences is based in New York, New York.